On Monday, 4D Molecular Therapeutics Inc (NASDAQ: FDMT) opened lower -11.02% from the last session, before settling in for the closing price of $3.63. Price fluctuations for FDMT have ranged from $3.45 to $31.87 over the past 52 weeks.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Healthcare Sector giant saw their annual sales surged by 101.44% over the last five years. Company’s average yearly earnings per share was noted -20.38% at the time writing. With a float of $39.63 million, this company’s outstanding shares have now reached $45.79 million.
The firm has a total of 227 workers. Let’s measure their productivity. In terms of profitability, gross margin is 100.0%, operating margin of -507678.38%, and the pretax margin is -434778.38%.
4D Molecular Therapeutics Inc (FDMT) Breakdown of a Key Holders of the stock
A key investor’s attitude towards the stock of the Biotechnology industry is another important factor to consider. The insider ownership of 4D Molecular Therapeutics Inc is 14.40%, while institutional ownership is 92.02%. The most recent insider transaction that took place on Sep 16 ’24, was worth 8,165. In this transaction Chief Legal Officer of this company sold 500 shares at a rate of $16.33, taking the stock ownership to the 6,781 shares. Before that another transaction happened on Aug 19 ’24, when Company’s Chief Legal Officer sold 500 for $15.00, making the entire transaction worth $7,500. This insider now owns 6,781 shares in total.
4D Molecular Therapeutics Inc (FDMT) Recent Fiscal highlights
Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.89 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around -20.38% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will plunge by -4.47% during the next five years compared to -9.89% drop over the previous five years of trading.
4D Molecular Therapeutics Inc (NASDAQ: FDMT) Trading Performance Indicators
Check out the current performance indicators for 4D Molecular Therapeutics Inc (FDMT). In the past quarter, the stock posted a quick ratio of 14.92. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 3739.00.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -3.16, a number that is poised to hit -0.87 in the next quarter and is forecasted to reach -3.81 in one year’s time.
Technical Analysis of 4D Molecular Therapeutics Inc (FDMT)
Analysing the last 5-days average volume posted by the [4D Molecular Therapeutics Inc, FDMT], we can find that recorded value of 0.69 million was lower than the volume posted last year of 0.8 million. As of the previous 9 days, the stock’s Stochastic %D was 13.51%. Additionally, its Average True Range was 0.32.
During the past 100 days, 4D Molecular Therapeutics Inc’s (FDMT) raw stochastic average was set at 1.08%, which indicates a significant decrease from 5.10% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 69.69% in the past 14 days, which was lower than the 78.58% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $4.55, while its 200-day Moving Average is $10.60. Now, the first resistance to watch is $3.45. This is followed by the second major resistance level at $3.67. The third major resistance level sits at $3.82. If the price goes on to break the first support level at $3.09, it is likely to go to the next support level at $2.94. Now, if the price goes above the second support level, the third support stands at $2.72.
4D Molecular Therapeutics Inc (NASDAQ: FDMT) Key Stats
There are currently 46,302K shares outstanding in the company with a market cap of 149.56 million. Presently, the company’s annual sales total 40 K according to its annual income of -160,870 K. Last quarter, the company’s sales amounted to 0 K and its income totaled -43,840 K.
